- Q3 revenue $1.214B, +10% as reported and organic
IDEXX Laboratories reported Q3 revenue of $1.214 billion, up 10% as reported and organic, and EPS of $4.01, up 18% as reported and 22% on a comparable basis. CAG Diagnostics recurring revenue grew 11% as reported and organic. The company raised its 2026 revenue guidance to $4.741-$4.767 billion and EPS outlook to $14.96-$15.16.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.